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In an effort to clear persistent HIV infection and achieve a durable therapy-free remission 
of HIV disease, extensive pre-clinical studies and early pilot clinical trials are underway 
to develop and test agents that can reverse latent HIV infection and present viral antigen 
to the immune system for clearance. It is, therefore, critical to understand the impact 
of latency-reversing agents (LRAs) on the function of immune effectors needed to clear 
infected cells. We assessed the impact of LRAs on the function of natural killer (NK) 
cells, the main effector cells of the innate immune system. We studied the effects of 
three histone deacetylase inhibitors [SAHA or vorinostat (VOR), romidepsin, and pano-
binostat (PNB)] and two protein kinase C agonists [prostratin (PROST) and ingenol] on 
the antiviral activity, cytotoxicity, cytokine secretion, phenotype, and viability of primary 
NK cells. We found that ex vivo exposure to VOR had minimal impact on all parame-
ters assessed, while PNB caused a decrease in NK cell viability, antiviral activity, and 
cytotoxicity. PROST caused non-specific NK cell activation and, interestingly, improved 
antiviral activity. Overall, we found that LRAs can alter the function and fate of NK cells, 
and these effects must be carefully considered as strategies are developed to clear 
persistent HIV infection.
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inTrODUcTiOn
The recent description of an HIV-1 infected individual who experienced a sterilizing cure (1), 
without evidence of replication-competent virus in vivo, and others in whom early antiretroviral 
therapy (ART) resulted in undetectable viremia and maintenance of immune competence despite 
the cessation of ART (a functional cure) (2), has given rise to a variety of experimental approaches 
to induce cure or drug-free remission of HIV-1 infection. The most intensively studied eradication 
strategy [known as “shock and kill” (3)] rests on inducing viral expression within latently infected 
Abbreviations: IFN-γ, interferon-gamma; ING, ingenol; LRA, latency reversing agents; PNB, panobinostat; PROST, prostratin; 
RMD, romidepsin; VOR, vorinostat.
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CD4+ T cells, with the goal of reducing the reservoir size through 
viral cytopathic effects (CPE) or immune-mediated clearance. 
However, recent in vitro experiments demonstrated that proviral 
reactivation alone did not result in viral CPE, and the autologous 
HIV-1 specific CD8+ T cells of patients were unable to clear reac-
tivated cells (4). Clearly, the capacity of the host immune system 
to recognize and kill infected cells upon reactivation requires 
closer evaluation.
Histone deacetylase (HDAC) inhibitors and protein kinase C 
(PKC) agonists are two promising classes of latency-reversing 
agents (LRAs) that are undergoing extensive testing in in vitro 
models and in initial pilot clinical trials to reactivate latent 
HIV-1 infection. HDAC inhibitors were developed as antican-
cer drugs as HDACs play important roles in epigenetic and 
non-epigenetic transcriptional regulation, inducing apoptosis 
and cell cycle arrest (5). In the context of HIV-1 reactivation, 
HDAC inhibitors induce transcription at the HIV-1 long 
terminal repeat (LTR) (6–9). PKC agonists induce latent viral 
expression though NF-κB signaling (10). Members of these 
two LRA classes have demonstrated efficacy in inducing HIV-1 
expression in cells from patients on ART in vivo and in vitro (9, 
11–16). However, as both histone deacetylation and signaling 
through NF-κB may impact the function of diverse cell popula-
tions, the effect of LRAs beyond latently infected cells must be 
carefully evaluated.
The influence of LRAs on cytotoxic T-lymphocytes (CTL) 
has recently been assessed. In one in vitro study, selected HDAC 
inhibitors caused a negative impact on CTL effector function 
(17), although in both this study and in another study that 
focused on vorinostat (VOR) (18), little effect of a pharmacologi-
cally relevant exposure to VOR was seen. CD8+ T cells are a 
well-studied and crucial effector cell population contributing 
to target cell clearance after viral reactivation. However, other 
effector subsets may also play an important role, including cells 
from the innate immune system. Natural killer (NK) cells are 
the main effectors of the innate immune response. NK effector 
function is elicited immediately upon recognition of activat-
ing ligands without prior exposure to the infected cell or to 
viral antigens, resulting in direct lysis of target cells and/or 
promotion of antibody-dependent cellular cytotoxicity (ADCC) 
(19). In addition, NK activity has been associated with HIV 
post-treatment control of viremia after treatment interruption 
(20), ADCC has been correlated with protection in a recent 
HIV-1 vaccine trial (21) and innate immune cell responses were 
correlated with HIV-1 DNA decline during panobinostat (PNB) 
treatment in vivo (22). Thus, multiple lines of evidence suggest 
the relevance of NK cells in the clearance of persistent HIV-1 
infection.
In the present study, we aim to better understand the impact 
of LRAs on the innate immune system, and specifically on 
NK cells. LRAs might impact the capacity of NK cell to clear 
infected cells in at least two ways: (i) through a direct impact on 
immune effector cells, causing activation, toxicity, or modifying 
receptor expression and cytotoxicity capacity or (ii) affecting 
the expression of ligands in the target population modifying 
effector recognition and subsequent clearance. Herein, we 
analyze both the direct impact of candidate compounds from 
two promising LRA classes on NK cells, and the effects on ligand 
expression on target cells ex vivo, as a means of informing HIV-1 
eradication strategies making use of these agents in future pilot 
clinical trials.
MaTerials anD MeThODs
cell samples
Peripheral blood mononuclear cells (PBMC) were obtained 
by Ficoll gradient from buffy coats of HIV-1 negative healthy 
donors, under approval of the UNC Biomedical Institutional 
Review Board. NK and CD4+ T cells were magnetically isolated 
from the PBMCs by negative selection (StemCell Technologies, 
Vancouver, BC, Canada). The NK cell enrichment antibody 
cocktail included monoclonal antibodies against CD3, CD4, 
CD14, CD19, CD20, CD36, CD66b, CD123, HLA-DR, and 
glycophorin A. The CD4+ T cell enrichment antibody cocktail 
included specific antibodies against CD8, CD14, CD16, CD19, 
CD20, CD36, CD56, CD66b, CD123, TCR-γ/δ, and glycophorin 
A. After isolation, NK cells were cultured in Iscove’s Modified 
Dulbecco’s Medium (IMDM) supplemented with 10% heat 
inactivated bovine serum and 5% penicillin plus streptomycin 
(cIMDM), including or not the different LRAs at the appropriate 
concentrations for 24 h. Then, cells were washed and functional 
assays performed.
ethics statement
Study participants provided written informed consent under a 
protocol that was approved by the UNC Biomedical Institutional 
Review Board.
latency-reversing agents
The compounds comprising our LRA panel were provided, 
and stocks prepared, by the CARE Pharmacology Core of the 
University of North Carolina. VOR was donated by Merck, and 
romidepsin (RMD) and PNB obtained from Selleckhem. For all 
three, a 10 mM stock was prepared in DMSO, and further diluted 
with IMDM to a working stock concentration of 25 μM (VOR) 
or 5 μM (RMD and PNB). Prostratin (PROST) was purchased 
from Cayman Chemical (Ann Arbor, MI, USA) in an ethanol 
solution, which was lyophilized and reconstituted with DMSO 
to a concentration of 5 mM, and further diluted in plain IMDM 
to a working stock solution of 25  μM. Ingenol (ING) 3-20 
dibenzoate was obtained from Santa Cruz Biotechnology; stock 
solution was prepared in DMSO at a concentration of 1  mM 
and diluted to working stock concentration of 25 μM with non-
supplemented IMDM. All stocks and working solutions were 
stored at −20°C and used avoiding repeated freezing–thawing 
cycles. LRA concentrations used in the experiments were selected 
based on pre-clinical data to reflect the potential physiological 
concentration (23–25). VOR was used at a concentration of 
335 nM, RMD at 10 nM, PNB at 20 nM, PROST at 1000 nM, 
and ING at 100  nM. If physiologic (in  vivo) data were not 
available for selecting a concentration, concentrations were 
chosen to reflect dosing previously shown to be effective in 
HIV-1 reactivation in ex vivo studies (11, 26, 27). In addition, 
a lower and a higher dose of the one considered physiological 
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were tested in some experiments to determine if there was a 
dose-dependent relationship.
Viral inhibition assays
CD4+ T cells were isolated by negative selection in parallel to NK 
cells from each donor. Isolated CD4+ T cells were activated during 
24 h with 2 μg/mL PHA (Sigma Aldrich, St Louis, MO, USA) and 
60 U/mL IL-2 (Peprotech, Rocky Hill, CT, USA). Cells were then 
infected with the JR-CSF viral strain by spinoculation for 90 min 
at 2500 rpm. After spinoculation, cells were extensively washed 
to remove free virions and 50,000 CD4+ T cells were plated in 
triplicate for each condition in a 96-well plate. NK cells, previ-
ously exposed to LRAs or not (reference control), were added to 
the wells in an effector:target (E:T) ratio of 1:1, and left in culture 
for 7 days in cIMDM with 5 U/mL IL-2, with a media change at 
day 4. Viral production was assessed in the supernatant by p24 
ELISA (ABLinc, Rockville, MA, USA), and percentage of viral 
inhibition of the different conditions was compared to inhibi-
tion from untreated NK cells. To assess the impact of LRAs on 
cell population proportion, we performed FACS analysis of the 
cells at the end of the viral inhibition assay. Cells were harvested 
and surface stained with CD3-PerCP, CD4-FITC, and CD56-PE 
(BD). The proportion of CD4+ T cells was evaluated in the CD3+ 
population, while the proportion of NK cells was evaluated in the 
whole sample. For the blocking experiments, NKG2D blockade 
was performed incubating PROST-treated NK cells with pure 
NKG2D (Miltenty Biotec) during 30 min at room temperature 
before starting the viral inhibition culture. Success of blockade 
was checked by flow cytometry.
Toxicity assay
Natural killer cells were cultured in cIMDM in the presence or 
absence of the individual LRAs from our panel for 24 h. After 
washing, cells were re-suspended in Annexin binding buffer 
and stained with Annexin V-FITC and 7-AAD (Biolegend, San 
Diego, CA, USA) following manufacturers’ protocol. Samples 
were analyzed on the Attune Focusing Cytometer (Applied 
Biosystems), and the percentage of double-positive cells for 
both Annexin V and 7-AAD was considered as the non-viable 
population.
cytotoxicity, iFn-γ Production,  
and non-specific activation assays
Natural killer cytotoxicity and IFN-γ production were analyzed in 
co-cultures of primary NK cells and K562 cells (an NK-sensitive 
target cell line that lacks MHC-I molecules) with and without 
previous exposure of the NK cells to individual LRAs from our 
panel. Cytotoxicity was assessed by analyzing the expression 
of the degranulation marker CD107a, a reliable marker of NK 
cell cytotoxic activity (28). A total of 100,000 NK cells were co-
cultured with the same number of K562 target cells in 96-well 
plates for 4–6  h in the presence of PE/Cy7-CD107a antibody, 
clone H4A3 (BD), adding 1 μL of GolgiStop (BD) after the first 
hour of culture. Cells were then harvested, washed, and surface-
stained with CD56-FITC, clone NCAM 16 (BD) in staining buffer 
for 20 min on ice in the dark. Cells were then fixed with Fixation 
buffer (Biolegend, San Diego, CA, USA) during 20 min at room 
temperature in the dark, washed with Perm/Wash buffer twice 
and intracellularly stained with IFNγ-PE (Biolegend, San Diego, 
CA, USA) for 20 min. After washing, cells were re-suspended in 
staining buffer and analyzed in the Attune Focusing Cytometer 
(Applied Biosystems). To analyze whether NK cells were non-
specifically activated by LRA, NK cells were also incubated in the 
absence of target cells, and CD69 (CD69-PE, clone FN50, from 
BD) and CD107a expression was analyzed as described.
expression of activating receptors  
in nK cells
A panel of NK cell activating receptors was analyzed by flow 
cytometry comparing untreated NK cells and cells exposed to 
individual LRAs from our panel. The following surface mono-
clonal antibodies were used: CD56-APC/Cy7 (clone HCD56), 
CD16-Pacific Blue (clone 3G8), NKG2D-Brilliant Violet 510 
(clone 1D11), NKp30-PE (clone P30-15), NKp44-AlexaFluor 647 
(clone P44-8), NKp46-PE/Cy7 (clone 9E2), and DNAM-1-FITC 
(clone 11A8) (all from Biolegend, San Diego, CA, USA). Samples 
were analyzed on LSR Fortessa (Becton Dickinson) cytometer. 
The expression of each of the receptors was analyzed on the 
CD56+ population using FlowJo X software (Ashland, OR, USA). 
To set the gates, fluorescence minus one (FMO) controls were 
used for each individual experiment.
expression of nK ligands on 
resting cD4+ T cells
Primary resting CD4+ T cells were isolated from healthy HIV-
uninfected donors and cultured in vitro with individual LRAs from 
our panel. After 24 h in culture with the LRAs, cells were washed 
and stained with antibodies against seven different NK ligands. 
Antibodies used included NTB-A (clone NT-7, Biolegend), 
HLA-E (clone 3D12, Biolegend), Bw4 (clone REA274, Miltenyi 
Biotec), CD155 (clone TX24, Biolegend), ULBP-1 (clone 170818, 
R&R Systems), ULBPB-2 (clone 16590, R&R Systems), and CD48 
(clone TU145, BD Pharmingen). Flow cytometry was performed 
to analyze for changes in cell surface expression. Median intensity 
of fluorescence was compared to medium/carrier solvent alone 
(negative control, dimethyl sulfoxide).
statistical analysis
Statistical analyses were performed using GraphPad Prism version 
6.07 (GraphPad Software, La Jolla, CA, USA). Data are presented 
either as raw values or fold change (FC) normalized to untreated 
NK cells for each of the experiments. Statistical significance was 
determined with a Wilcoxon matched-pairs signed rank test.
resUlTs
nK cell antiviral activity improves after 
Prostratin exposure but it is impaired after 
Panobinostat and ingenol Treatment
Viral inhibition capacity of NK cells was tested in autologous 
cell systems, using NK and CD4+ T cells from the same donor. 
The average purity of NK cells after isolation – measured as 
FigUre 1 | antiviral activity of nK cells. Percentage HIV replication 
inhibition after 7 days of culture, normalized to untreated NK cells. CD4+ 
T cells were isolated, stimulated, and infected with JR-CSF. Infected 
targets were cultured with autologous NK cells in triplicate at a 
ratio 1:1. Each color represents cells from a different donor. At 
physiologically relevant doses, VOR and RMD did not have significant 
impact in the antiviral activity of the NK cells, while exposure to PNB 
and ING impaired NK cell viral inhibition capacity. On the contrary, NK 
treatment with PROST improves antiviral activity of NK cells. p-values 
were calculated using a Wilcoxon matched-pairs signed rank test. 
N =  12. VOR, vorinostat; RMD, romidepsin; PNB, panobinostat; PROST, 
prostratin; ING, ingenol.
4
Garrido et al. LRA Impact on NK Cells
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 356
the proportion of CD3−CD56+ – was of 91.26% (SEM =  1.5), 
and the purity of CD4 cells – measured as the proportion of 
CD3+CD4+ – was 93.22 (SEM =  1.6). Results obtained from 
LRA-treated NK cell conditions were normalized to viral inhi-
bition observed in the untreated NK cell condition. Exposure 
of NK cells to VOR did not impact the capacity of NK cells to 
reduce viral replication. However, NK treatment with RMD, 
PNB, and ING reduced the percentage of viral inhibition 
(RMD: 79.22%, p = 0.176; PNB: 58.6%, p = 0.016; ING: 67.69%, 
p =  0.001). Interestingly, PROST exposure improved antiviral 
activity of NK cells (159.5%, p = 0.002) (Figure 1, Figure S1 in 
Supplementary Material).
To elucidate the mechanisms by which some drugs altered 
NK cell antiviral activity, we investigated the direct impact of 
exposure to such drugs on NK cytotoxicity, IFN-γ production, 
viability, activation, and receptor expression. In addition, at the 
end of the viral inhibition assay, the cells present in the cultures 
were stained for NK cell markers (CD56) and T cell markers 
(CD3 and CD4). Interestingly, we found that proportion of NK 
cells increased following PROST exposure (153%, SEM = 14.0, 
p =  0.03), while the frequency of CD4 cells within the CD3+ 
population was diminished in the PROST-treated NK group 
compared to the untreated and all the other conditions (88.1%, 
SEM 2.7, p = 0.03). The increased frequency of NK cells in the 
culture with PROST was primarily due to an increase in the 
CD56bright population (216.7%, SEM 28.1, p =  0.03). For three 
donors, we also analyzed absolute numbers of cells, finding that 
PROST treatment increased cell number, specifically NK number 
(Figure S2 in Supplementary Material). Finally, we performed a 
three viral inhibition assays blocking the activating receptor 
NKG2D, showing that blockade of NKG2D in PROST-treated 
NK cells caused a decrease in viral inhibition capacity (average 
of 17.43% viral inhibition after blocking of NKG2D compared to 
36.12% without blocking, Figure S3 in Supplementary Material).
romidepsin and Panobinostat are Toxic to 
nK cells
Isolated NK cells were exposed to LRAs for 24  h, washed and 
stained with Annexin V-FITC and 7-AAD. Dead cells were 
identified as double-positive cells for Annexin V and 7-AAD 
(Figure  2A). We observed a general trend toward a decrease 
in viability after exposure to all drugs (p  =  0.02) except for 
ING (p =  0.53), but the impact of RMD and PNB was more 
pronounced, with a mean FC of 2 and 2.5 for RMD and PNB, 
respectively, compared to VOR and PROST (mean FC = 1.3 and 
1.2, respectively) (Figure 2B). In addition, exposure to increas-
ing concentrations of RMD and PNB decreased cell viability in 
a dose-dependent manner, while viability of NK cells was not 
reduced following exposure to higher concentrations of VOR, 
PROST, or ING (Figure S4 in Supplementary Material). As the 
observed dead cell numbers were high, we compared the viability 
of untreated NK cells right after isolation and after 24 h in culture. 
We observed an increase of the apoptotic population (measured 
as Annexin V+) from 14.8 to 32%. This high rate of cellular death 
may be due to the lack of IL-15 or IL-2 in the culture.
lra impact on nK cell-Mediated 
cytotoxicity
Natural killer cytotoxicity was measured by analyzing the expres-
sion of CD107a after co-culture with K562 cells (Figure  3A). 
Exposure to a physiologically relevant concentration of 
RMD, PNB, and ING impaired the cytotoxic capacity of NK 
cells, as shown by a significant decrease in the proportion of 
CD56+CD107a+ cells (p < 0.0001). However, VOR and PROST 
did not have a significant impact on NK cytotoxic function 
(Figure 3B). The observed impairment in NK cell cytotoxic func-
tion caused by RMD, PNB, and ING was not due to a direct effect 
on the viability of NK cells, as we checked in cytotoxic function 
assays, including a viability stain (Annexin V-FITC and 7-AAD, 
n = 4 donors; data not shown).
We further analyzed whether the impairment in cytotoxic 
activity was dose dependent. NK cell cytotoxicity showed a 
dose-dependent reduction after exposure to RMD and PNB, and 
to some extent to VOR. Interestingly, a higher dose (1000 nM) 
of ING showed a slight improvement in NK cytotoxic function 
compared to 100 nM (Figure S5 in Supplementary Material).
Panobinostat and Prostratin impair iFn-γ 
secretion
Interferon-gamma secretion is an antiviral mechanism employed 
by NK cells and leads to recruitment and modulation of the 
activity of other effector cells, including CD8+ T cells (29). We 
analyzed IFN-γ production after a 4–6 h culture with K562 target 
cells (Figure 4A). FACS analysis after intracellular IFN-γ staining 
FigUre 2 | Toxicity of lras on nK cells. Proportion of dead NK cells after 24-h exposure to the different LRAs. (a) Representative FACS analysis showing the 
gating strategy to identify dead cells according to Annexin V and 7-AAD staining. Cell death was considered when cell were double positive for Annexin V and 
7-AAD. (B) Proportion of dead NK cells after exposure to the different LRAs, expressed as fold change relative to the untreated condition. Each color represents 
cells from a different donor. There was a general trend toward a decrease in viability after exposure with all drugs except for ING, but RMD and PNB impact was 
more pronounced and significantly higher than VOR, PROST, or ING (p < 0.02). N = 7.
FigUre 3 | cytotoxicity of nK cells. Proportion of CD56+CD107a+ cells after 4–6 h culture with K562 cells, expressed as fold change (FC) relative to untreated 
NK cells. (a) Representative FACS analysis plots showing the gating strategy. (B) Proportion of CD56+ cells expressing the degranulation marker CD107a. Each 
color represents cells from a different donor. Exposure to PNB, RMD and ING significantly impaired NK degranulation. N = 23.
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demonstrated that treatment with VOR modestly increased the 
percentage of NK cells that produced IFN-γ compared to untreated 
NK cells; however, this did not reach statistical significance. On 
the contrary, treatment with PNB or PROST resulted in a signifi-
cant reduction in the number of IFN-γ+ NK cells (p = 0.05 and 
p = 0.01, respectively) (Figure 4B).
FigUre 4 | cytokine production. Proportion of CD56+IFN-γ+ cells after 4–6 h culture with K562 cells. (a) Representative FACS analysis showing gating strategy 
after intracellular staining with IFN-γ. (B) Proportion of CD56+ cells positive for IFN-γ expressed as fold change relative to the untreated NK condition. Each color 
represents cells from a different donor. VOR, RMD, or ING do not have a significant effect on IFN-γ production, while PNB and PROST impaired cytokine production. 
N = 12.
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PKc agonists cause non-specific nK cell 
activation
To measure non-specific NK cell activation caused by exposure 
to LRAs, expression of CD69, CD107a, and IFN-γ was measured 
in the absence of target cells or any other stimulus. Exposure 
to all drugs caused non-specific activation as measured by 
CD69 expression (p  =  0.01), although activation was much 
greater after treatment with PROST and ING (27- and 14-fold, 
respectively). Among the HDACi tested, PNB led to an increase 
in CD69 expression of nearly 10-fold, while VOR and RMD only 
produced 1.5- and 2.2-fold increase. In addition, exposure to 
the PKC agonist PROST caused marked increase in CD107a, 
while the increase caused by ING was more variable (p = 0.01 
and p = 0.06, respectively; Figure 5). IFN-γ production in the 
absence of target cells was also assessed, and no change was 
observed after exposure to any of the LRA (data not shown). 
Figure S6 in Supplementary Material show these results as 
raw data.
expression of activating receptors on 
nK cells is Downregulated by exposure 
to PnB
Natural killer cells express a wide variety of receptors that enable 
them to differentiate infected or tumor cells from healthy cells. 
These include inhibitory, activating, adhesion, and cytokine 
receptors. The balance of these signals determines whether the 
NK cell becomes activated or not (30). For this study, we analyzed 
the expression of activating receptors that have been identified 
to be important for antiviral activity of NK cells. These included 
CD16, NKG2D, DNAM-1, NKp30, NKp44, and NKp46 (31). 
Their expression was measured by flow cytometry after gating 
on the CD56+ population (Figure  6). PNB exposure caused a 
significant decrease in the expression of all receptors except 
from NKp44: CD16 (p =  0.05), NKG2D (p =  0.05), DNAM-1 
(p =  0.01), NKp30 (p =  0.01), and NKp46 (p =  0.01). On the 
contrary, exposure to ING increased the expression of most of 
the receptors: CD16 (p =  0.05), NKG2D (p =  0.005), NKp30 
(p = 0.005), and NKp46 (p = 0.01). PROST also caused a signifi-
cant increase in NKG2D expression (p = 0.005), but a decrease in 
CD16 (p = 0.005). Figure S7 in Supplementary Material shows a 
representative example of the expression of the activating recep-
tors in the presence of these agents.
impact of lras on nK ligand expression 
in resting cD4+ T cells
We analyzed by flow cytometry the expression of some ligands 
on target cells that either trigger NK activation or initiate 
inhibitory NK signaling by binding to NK inhibitory receptors. 
The activating ligands included NTB-A, which binds NTB-A 
on the NK cell surface and leads to activation and secretion of 
interferon-γ, CD48, which binds 2B4, ULBP-1 and -2, ligands 
that bind NKG2D and that have been demonstrated to be 
upregulated in the setting of HIV-1 infection by the viral protein 
vpr (32), and CD155, a NK ligand that binds DNAM-1 on NK 
cells and induces activation (33). The inhibitory included HLA-E 
FigUre 5 | non-specific activation of nK cells. Expression of activation markers on NK cells in the absence of target cells or any other stimuli. Graphs 
represent log10 of the fold change relative to untreated NKs and each color represents cells from a different donor. (a) Expression of CD69. (B) Expression of 
CD107a. Exposure to all drugs caused some unspecific activation as measured by CD69 expression, but exposure to the PKC agonists were the most remarkable. 
PROST also caused a significant increase in CD107a expression. N = 8.
FigUre 6 | expression of activating receptors on nK cells. Results are expressed as fold change relative to untreated NK cells and each color represents cells 
from a different donor. PNB caused a general decrease in the expression of activating receptors, as opposed to ING, which caused a significant increase in the 
expression of all receptors except DNAM1 and NKp44. Of interest, PROST produced a significant increase in the expression of NKG2D. N = 9.
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and HLA-Bw4, NK ligands that initiate inhibitory NK signaling 
by binding to NK receptors NKG2A and KIR3DL1, respectively. 
The expression of most activating ligands on resting CD4+  
T cells were unaffected by the LRAs tested, with the exception of 
CD155, which increased its expression in the presence of both 
PKC agonists [2.3-fold increase with PROST (p =  0.01) and 
2.1-fold increase with ING (p = 0.02)], as well as PNB (1.7-fold 
increase, p = 0.02). Regarding inhibitory ligands, PKC agonists 
8Garrido et al. LRA Impact on NK Cells
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significantly upregulated expression of HLA-E (ING: twofold, 
p = 0.005; PROST: 2.3-fold, p = 0.01) and Bw4 (ING: 2.6-fold, 
p = 0.01, PROST: 2.8-fold, p = 0.01). None of the HDACi sig-
nificantly affected HLA-E expression, although modest trends 
for decreased HLA-Bw4 expression were observed with all 
HDACi, reaching statistical significance for VOR (p =  0.05). 
In sum, exposure to PKC agonists PROST and ING significantly 
increased two inhibitory NK ligands (HLA-E and HLA-Bw4) 
and one activating ligand (CD155) on the cell surface of primary 
CD4+ T cells, while HDACi exposure had little effect on NK 
ligand expression on resting CD4+ T cells (Figure 7).
DiscUssiOn
For successful implementation of the HIV eradication strategy 
of latency reversal and clearance, LRAs doses and administra-
tion regimens must be selected so that they induce viral antigen 
expression in latently infected cells but do not interfere with 
the clearance function of immune effector cells. In this study, 
we have evaluated the impact of five LRAs on NK cell function. 
Overall, we observed a heterogeneous effect of the different LRAs 
evaluated, differing even within each drug class. VOR did not 
have any significant effect on any of the parameters of NK cell 
function or viability, while exposure to the other HDACi tested, 
RMD and PNB, had deleterious effects. Particularly, PNB caused 
a significant decrease in cytotoxicity, antiviral activity, activating 
receptor expression, and cytokine secretion of NK cells, along 
with a decrease in viability. A similar trend was observed for 
RMD, but milder that the observed with PNB. PKC agonists 
induced expression of some markers of activation in NK cells and, 
remarkably, PROST exposure lead to an improvement in antiviral 
activity.
To our knowledge, no studies of the impact of PNB or PKC 
agonists on NK cell function have been performed. A previous 
study reported VOR suppression of NK cell cytolytic activity 
by impairing granule exocytosis and decreasing expression of 
activating receptors (34). However, a 96-h incubation with the 
drug was carried out in those experiments, which exceeds the 
in vivo pharmacokinetic exposure to VOR, cleared in less than 
6 h (35). On the contrary, we did not observe any negative impact 
of VOR on NK cell function. Clinical treatment with RMD in 
patients with cutaneous T-cell lymphoma induced a decrease of 
NK cell cytolytic activity, similar to our ex vivo results, although 
interestingly the activity was restored after stimulation with a 
toll-like receptor agonist (36).
Here, we observed that PNB exposure caused a decrease in the 
antiviral activity of NK cells. This impairment in viral inhibition 
was likely due to the reduction in cytotoxicity and IFN-γ produc-
tion that we also observed, as well as the down-modulation of 
important activating receptors, such as NKG2D, on the surface 
of the NK cells. In addition, PNB decreased NK cell viability, so 
at least part of the decreased antiviral activity observed in the 
viral inhibition experiments could be due to an actual reduction 
of number of NK cells in culture, with a consequent reduction 
in E:T cell ratio. In fact, using our whole dataset, we found that 
both cytotoxicity and cell viability correlated significantly with 
a decrease in antiviral activity (Figure S8 in Supplementary 
Material). PNB has been shown in a study to be the most potent 
of all HDAC inhibitors (37), and could represent a very promising 
option for HIV reactivation. However, our in vitro results point 
out the potential deleterious effects that PNB can have on NK 
cell function, and this should be monitored in future clinical 
studies. Interestingly, the recent in  vivo pilot clinical trial with 
PNB observed that patients with more pronounced proviral DNA 
FigUre 7 | nK ligand expression on resting cD4+ T cells in the presence of lras. LRAs had little effect on NK ligand expression with the exception of PKC 
agonists, which caused increased expression of the inhibitory NK ligands HLA-E and HLA-Bw4 as well as activating ligand CD155. Median fluorescence intensity 
was compared to the medium/carrier solvent alone condition (negative control, dimethyl sulfoxide). N = 8.
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decline during PNB treatment had a higher frequency of NK cells 
(22), suggesting that the function of the innate immune system 
should be monitored during latency reversal and clearance 
studies.
On the other hand, we observed an improvement in NK 
antiviral activity after exposure to PROST. This observation could 
be due to the increase in NK activation upon culture with the 
drug; however, it is also possible that PROST remained attached 
to cellular membranes despite washing after drug exposure as has 
previously been suggested (38), leading to blunted HIV infection 
in target cells. When we analyzed the cell composition of the cul-
tures after a 7-day viral inhibition assay, we consistently observed 
that in the cultures where NK cells were exposed to PROST, the 
CD3−CD56+ subset was increased compared to all the other 
conditions, with an especially marked increase in the CD56bright 
population, while the proportion of cells expressing CD4 within 
the CD3+ population was decreased. Moreover, exposure to 
PROST upregulated the expression of NKG2D, which is a NK cell 
activating receptor known for its importance in NK cell antiviral 
activity (39, 40). Thus, the increase in antiviral activity observed 
after PROST exposure was most likely due to a combination 
of several effects, including changes in both the target popula-
tion and in the effector population. This may have interesting 
implications for in  vivo HIV-1 eradication strategies in which 
PKC agonists might simultaneously induce several desirable 
effects: reactivation of latently infected cells, inhibition of viral 
replication, and enhancement of the antiviral effect of NK cells. 
ING, the other PKC agonist tested in our experiments, did not 
have such a marked effect in any of the functional characteristics 
analyzed, but we did observe upregulation of NKG2D and some 
activation measured by CD69. Beyond the specific characteristics 
of each of these components of the PKC agonist family, a possible 
reason for the difference in the magnitude of the effect observed 
with PROST and ING could be the dose of each drug used in 
our experiments. In fact, when a higher dose (1 μM) of ING was 
used for the viral inhibition experiments, an improvement in NK 
cell antiviral activity was observed (mean of twofold compared 
to untreated NK cells, Figure S9 in Supplementary Material). 
However, we also observed a decrease in IFN-γ production when 
NK cells were exposed to PKC agonists. This conflicts with our 
observations of the increase of the CD56bright population, given 
that generally CD56dim subpopulations are more cytotoxic, while 
CD56bright are able to produce IFN-γ (41). We also observed a 
decrease in CD16 expression on NK cells treated with PROST, 
which in this case would correlate with the increase in the 
CD56bright subpopulation, as CD16 is expressed largely in CD56dim 
subsets. Down-modulation of CD16 is concerning given that 
ADCC is mediated by antibody engagement to this receptor, and 
further study is required to determine whether this decrease in 
expression has functional consequences.
Our experiments were performed using unstimulated NK 
cells, with the aim of recapitulating in  vivo exposure to LRAs. 
However, for immunotherapeutic purposes, an alternative strat-
egy involves ex vivo stimulation and expansion of NK cells, with 
the intention of improving their cytotoxic potential. Susceptibility 
of these expanded cells to LRAs may differ from what we have 
observed in non-stimulated cells, as it has been already shown 
for impact on CTL (17). In fact, we observed a reduction in K562 
target cell lysis when expanded NK cells were exposed to PROST 
(data not shown). On the contrary, and although we did not 
observe relevant impact of VOR on NK cell function, Schmudde 
et al. reported an impairment of NK cell degranulation by VOR 
exposure when cells were not stimulated, but no impact if NK 
cells were previously stimulated with IL-2 (42).
In addition to investigating the direct impact of LRAs on 
NK cells, we analyzed the impact of exposure to these agents 
on target cells relevant for HIV infection (resting CD4+ T cells) 
to assess expression of surface ligands that would render them 
more susceptible to NK cell recognition and clearance. Overall, 
we did not observe a striking effect on ligand expression on CD4+ 
T cells, with the exception of a modest increase in HLA-E and 
BW4 (inhibitory ligands), and CD155 (an activating ligand) 
when cells were exposed to PKC agonists. Different observations 
have been reported from oncology studies, where it has been 
consistently reported that HDACi upregulate the expression of 
NKG2D ligands on tumor cells (43–46), helping their recognition 
by innate immune system. On the other hand, it has also been 
seen that HDACi can down-modulate the expression of NKp30 
ligands on tumor cells, reducing NKp30-dependent effector func-
tions of NK cells (47).
To achieve clinically significant reversal of HIV-1 latency, 
several studies suggest that combinations of mechanistically dif-
ferent LRA will be needed (48–50). Our results add an additional 
factor to consider when designing an adequate LRA combination, 
as not only reactivation potency should be taken into account but 
also the impact that each of the drugs have on immune effector 
function. Thus, if a certain LRA is selected to be used because of 
its potency for reactivating the reservoir but it has shown to cause 
an impair in immune function, the second component of the LRA 
combination ideally should have proven to cause an improvement 
to some extent in the effector activity. The optimum situation for 
cure strategies would be finding compounds that simultaneously 
can disrupt latency and boost the immune response, and some 
agents with these capabilities are beginning to be described (51).
In summary, we have evaluated ex vivo the impact of five 
different latency-reversing agents on the effector function, phe-
notype, and viability of NK cells. This is of clinical relevance given 
the necessity of a potent immune response after reactivation of 
the latent HIV reservoir in order to achieve viral eradication. We 
have found a heterogeneous effect of the different agents studied, 
highlighting the lack of impact of VOR, the negative effects of 
PNB and RMD, and the potential beneficial impact of PKC ago-
nists. Impact of LRA on immune function should be considered 
when designing LRA combinations to reactivate the latent HIV-1 
reservoir. This is the first study to address the impact of LRAs on 
innate immune functions in the context of HIV-1 eradication, 
and demonstrate the importance of further evaluation of NK 
cell function. However, in vitro results might differ from in vivo 
effects. Our analysis of the effect of LRAs on NK cell function is, 
of necessity, only a preliminary one. In clinical trials, multiple 
doses of LRAs will be given over time, a phenomenon that is 
more difficult to model. Thus, innate immune function should be 
evaluated in HIV-1 positive patients undergoing latency revers-
ing therapy.
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